149 related articles for article (PubMed ID: 20057308)
1. Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
Hudelson SE; McConnell MS; Bagenda D; Piwowar-Manning E; Parsons TL; Nolan ML; Bakaki PM; Thigpen MC; Mubiru M; Fowler MG; Eshleman SH
AIDS; 2010 Feb; 24(4):557-61. PubMed ID: 20057308
[TBL] [Abstract][Full Text] [Related]
2. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
Moorthy A; Gupta A; Bhosale R; Tripathy S; Sastry J; Kulkarni S; Thakar M; Bharadwaj R; Kagal A; Bhore AV; Patil S; Kulkarni V; Venkataramani V; Balasubramaniam U; Suryavanshi N; Ziemniak C; Gupte N; Bollinger R; Persaud D
PLoS One; 2009; 4(1):e4096. PubMed ID: 19119321
[TBL] [Abstract][Full Text] [Related]
3. In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
Church JD; Mwatha A; Bagenda D; Omer SB; Donnell D; Musoke P; Nakabiito C; Eure C; Bakaki P; Matovu F; Thigpen MC; Guay LA; McConnell M; Fowler MG; Jackson JB; Eshleman SH
AIDS Res Hum Retroviruses; 2009 Jul; 25(7):673-7. PubMed ID: 19552593
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine.
Aizire J; McConnell MS; Mudiope P; Mubiru M; Matovu F; Parsons TL; Elbireer A; Nolan M; Janoff EN; Fowler MG
J Acquir Immune Defic Syndr; 2012 Aug; 60(5):483-8. PubMed ID: 22217678
[TBL] [Abstract][Full Text] [Related]
5. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
Eshleman SH; Guay LA; Mwatha A; Cunningham SP; Brown ER; Musoke P; Mmiro F; Jackson JB
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
[TBL] [Abstract][Full Text] [Related]
6. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Chung MH; Kiarie JN; Richardson BA; Lehman DA; Overbaugh J; Kinuthia J; Njiri F; John-Stewart GC
Antivir Ther; 2008; 13(6):799-807. PubMed ID: 18839781
[TBL] [Abstract][Full Text] [Related]
7. Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
Pilger D; Hauser A; Kuecherer C; Mugenyi K; Kabasinguzi R; Somogyi S; Harms G; Kunz A
Antivir Ther; 2011; 16(1):109-13. PubMed ID: 21311114
[TBL] [Abstract][Full Text] [Related]
8. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
Palmer S; Boltz V; Martinson N; Maldarelli F; Gray G; McIntyre J; Mellors J; Morris L; Coffin J
Proc Natl Acad Sci U S A; 2006 May; 103(18):7094-9. PubMed ID: 16641095
[TBL] [Abstract][Full Text] [Related]
9. Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
Permar SR; Salazar MG; Gao F; Cai F; Learn GH; Kalilani L; Hahn BH; Shaw GM; Salazar-Gonzalez JF
Retrovirology; 2013 Aug; 10():88. PubMed ID: 23941304
[TBL] [Abstract][Full Text] [Related]
10. Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
Wagner TA; Kress CM; Beck I; Techapornroong M; Wittayapraparat P; Tansuphasawasdikul S; Jourdain G; Ngo-Giang-Huong N; Lallemant M; Frenkel LM
J Clin Microbiol; 2010 May; 48(5):1555-61. PubMed ID: 20181911
[TBL] [Abstract][Full Text] [Related]
11. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
12. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
Basson AE; Ntsala M; Martinson N; Tlale E; Corrigan GE; Shao X; Gray G; McIntyre J; Puren A; Morris L
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):538-43. PubMed ID: 18989222
[TBL] [Abstract][Full Text] [Related]
13. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Eshleman SH; Mracna M; Guay LA; Deseyve M; Cunningham S; Mirochnick M; Musoke P; Fleming T; Glenn Fowler M; Mofenson LM; Mmiro F; Jackson JB
AIDS; 2001 Oct; 15(15):1951-7. PubMed ID: 11600822
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
McIntyre JA; Hopley M; Moodley D; Eklund M; Gray GE; Hall DB; Robinson P; Mayers D; Martinson NA
PLoS Med; 2009 Oct; 6(10):e1000172. PubMed ID: 19859531
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
Cuco RM; Loquiha O; Juga A; Couto A; Meggi B; Vubil A; Sevene E; Osman N; Temermam M; Degomme O; Sidat M; Bhatt N
PLoS One; 2022; 17(2):e0261522. PubMed ID: 35143515
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission.
Lehman DA; Chung MH; John-Stewart GC; Richardson BA; Kiarie J; Kinuthia J; Overbaugh J
AIDS; 2008 Jul; 22(12):1475-85. PubMed ID: 18614871
[TBL] [Abstract][Full Text] [Related]
17. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
Flys TS; Donnell D; Mwatha A; Nakabiito C; Musoke P; Mmiro F; Jackson JB; Guay LA; Eshleman SH
J Infect Dis; 2007 Mar; 195(5):711-5. PubMed ID: 17262714
[TBL] [Abstract][Full Text] [Related]
18. Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Palmer S; Boltz VF; Chow JY; Martinson NA; McIntyre JA; Gray GE; Hopley MJ; Mayers D; Robinson P; Hall DB; Maldarelli F; Coffin JM; Mellors JW;
Antivir Ther; 2012; 17(2):327-36. PubMed ID: 22293443
[TBL] [Abstract][Full Text] [Related]
19. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
Boltz VF; Bao Y; Lockman S; Halvas EK; Kearney MF; McIntyre JA; Schooley RT; Hughes MD; Coffin JM; Mellors JW;
J Infect Dis; 2014 Mar; 209(5):703-10. PubMed ID: 24443547
[TBL] [Abstract][Full Text] [Related]
20. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
Persaud D; Bedri A; Ziemniak C; Moorthy A; Gudetta B; Abashawl A; Mengistu Y; Omer SB; Isehak A; Kumbi S; Adamu R; Lulseged S; Ashworth R; Hassen E; Ruff A;
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):823-9. PubMed ID: 21241214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
